PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study

BACKGROUND: The Kidney Disease Improving Global Outcomes (KDIGO) 2021 guidelines recommend Rituximab (RTX) as the first-line therapy and phospholipase A2 receptor (PLA2R) antibody as a biomarker for remission and prognosis in patients with idiopathic membranous nephropathy (IMN). METHODS: This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yiqing, Zhou, Junyi, Zhou, Kezhi, Huang, Biao, Xue, Jing, Zhang, Xiran, Liu, Bin, Zhang, Zhijian, Zhou, Leting, Cai, Ting, Zhang, Yi, Hu, Zhigang, Wang, Liang, Liu, Xiaobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2022
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559058/
https://www.ncbi.nlm.nih.gov/pubmed/36248712
http://dx.doi.org/10.7717/peerj.14193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559058/
https://www.ncbi.nlm.nih.gov/pubmed/36248712
http://dx.doi.org/10.7717/peerj.14193

Ejemplares similares